Aspire Biopharma Holdings (ASBP) Non-Current Debt (2023 - 2025)
Aspire Biopharma Holdings (ASBP) posted quarterly Non-Current Debt of $1.5 million for Q4 2025, up 222.08% year-over-year from $465722.0 in Q4 2024, and up 222.08% quarter-over-quarter from $465722.0 in Q4 2024.
Aspire Biopharma Holdings (ASBP) Non-Current Debt (2023 - 2025) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Non-Current Debt for 3 consecutive years, with $1.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Debt rose 222.08% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $1.5 million (up 222.08% YoY), while the FY2025 annual figure was $1.5 million, up 222.08% from the prior year.
- Non-Current Debt rose to $1.5 million in Q4 2025 per ASBP's latest filing, from $465722.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.5 million in Q4 2025 and bottomed at $12384.0 in Q4 2023.
- Historically, Non-Current Debt has averaged $509901.7 across 3 years, with a median of $432036.0 in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Debt jumped 3660.68% — and 2025, when it surged 222.08%.
- Aspire Biopharma Holdings' Non-Current Debt stood at $12384.0 in 2023, then surged by 3660.68% to $465722.0 in 2024, then soared by 222.08% to $1.5 million in 2025.
- Business Quant data shows ASBP's Non-Current Debt at $1.5 million in Q4 2025, $465722.0 in Q4 2024, and $436284.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 465,722.00 |
| Sep 30, 2024 | 436,284.00 |
| Jun 30, 2024 | 427,788.00 |
| Mar 31, 2024 | 217,232.00 |
| Dec 31, 2023 | 12,384.00 |